Current Project under Consideration for Partnership: (Strategy and Progress)

-Identified a crucial gene (PKCβ) responsible for obesity and fatty liver diseases.

-Established the role of PKCβ in diet-induced obesity using PKCβ knockout models. Mechanism   of action involves increased energy expenditure without affecting food intake.

-Screened compounds to test in vitro inhibition of PKCβ activity potently and specifically.

-Identified three small molecule PKCβ inhibitor compounds; INST3399 is one of them.

-Determined half-life of INST3399 by Mass Spec; NO evidence of toxicity; ALT down.

-Completed in vivo efficacy of one inhibitor (INST3399) using DIO obesity mouse model.

-INST3399 treatment attenuates diet-induced obesity, liver lipid accumulation and hypercholesterolemia

Planned Clinical Trials

  • INST-3399 novel drug developed by Instacare Therapeutics is ready for clinical trial for the treatment of Fatty Liver Disease

  • INST-3399 novel drug developed by Instacare Therapeutics is ready for clinical trial for the treatment of Hepatocellular carcinoma

  • INST-3579 novel drug developed by Instacare Therapeutics is ready for clinical trial for the treatment of Obesity